Due to the Covid-19 virus outbreak, Evonik’s contract manufacturer had to shut-down its production facilities. Both production and shipping of the amino acid ThreAMINO® are affected.
Dr. Emmanuel Auer, Head of Animal Nutrition Business Line at Evonik, explained: “Regrettably, we are facing a supply shortage for ThreAMINO®. We have therefore decided to send a Force Majeure notification to our customers with immediate effect, in accordance with our contracts. Meanwhile, we try the utmost to mitigate this situation and re-establish supply to our customers as fast as possible.”
Evonik is keeping its customers regularly informed as the situation develops.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,100 employees, and generated sales of around €4.58 billion in 2019.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.